Navigation Links
Effective new treatment for schizophrenia
Date:12/13/2007

Philadelphia, PA, December 13, 2007 Schizophrenia is one of the most debilitating of the major psychiatric disorders, and is also one of the most difficult to treat. Although numerous antipsychotic treatments are available, they can cause significant side effects and many patients experience only a partial relief of their symptoms and up to 30% no relief at all. In a new study scheduled for publication in the December 15th issue of Biological Psychiatry, Marder and colleagues examined the efficacy and safety of a new psychotropic agent for the treatment of schizophrenia in a 6-week, randomized, placebo-controlled trial.

The authors studied paliperidone extended-release (ER) tablets, an investigational drug which orally delivers the active metabolite of the drug risperidone, which is an already established efficacious antipsychotic. The authors recruited 444 patients who were experiencing an acute episode of schizophrenia and, after evaluating the severity of their symptoms, administered one of four treatments for 6 weeks: 6 mg or 12 mg/day of paliperidone ER, 10 mg/day of olanzapine (the active comparator), or placebo. During the six weeks of treatment, the investigators monitored the patients for side effects and assessed their symptom improvement.

Dr. Stephen Marder, senior author on the paper, explains the findings: This double-blind study found that two doses of paliperidone extended release tablets were more effective than placebo for treating the symptoms of acute schizophrenia. Patients receiving the most effective dose of paliperidone (6 mg) also demonstrated improvements in their social functioning. Jeffrey A. Lieberman, M.D., Chairman of the Department of Psychiatry at Columbia University and Director of the New York State Psychiatric Institute, comments, This study demonstrates the efficacy of the 9-hydroxy metabolite of risperidone that has antipsychotic efficacy and an acceptable safety profile which provides psychiatrists with yet another treatment option. It has practical advantages with its long half life, duration of action and extended release formulation. Dr. Lieberman cautions though that this finding is not a novel or breakthrough treatment and does not provide major differences or advantages over existing treatments. Additional studies are currently underway to further evaluate the long-term (up to one year) efficacy and safety of paliperidone ER in the treatment of schizophrenia.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
7. Case Management Cost-Effective Way to Cut Heart Risks
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Nasal Anthrax Vaccine Proves Effective in Animal Study
10. Family-based treatment more effective than supportive psychotherapy in treating bulimia
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Adolfson & Peterson Construction (AP) ... Ramsey County Medical Examiners Facility located in Saint Paul, Minn. A single story, ... scheduled to start in late 2017/early 2018. , Staffed by 20 full-time ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... OR (PRWEB) , ... July 21, 2017 , ... ... recent weeks Nature’s Tears® EyeMist®, the signature product of her research center at ... with the world’s largest population and the greatest number of sufferers of blindness. ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... TransPixel Volume ... between two clips in the FCPX timeline. This effect isolates horizontal and vertical lines ... this package contains either a rotating or flipping animation and can be changed using ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)...  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing ... dosage forms of existing biologically active molecule. ... Subveta oral ... emulsifying formula, which is designed to prevent precipitation of the ... will provide fast onset of action and is designed to ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 /PRNewswire/ ... validate the use of MMprofiler with SKY92, the company,s ... (MM). In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will ... elderly patients. In a separate e-poster ...
Breaking Medicine Technology: